U.S. ERECTILE DYSFUNCTION THERAPIES MARKET

119 Pages | 33 Exhibits | 2011 Analysis | Forecasts Through 2015

OVERVIEW:
Erectile dysfunction (ED) is estimated to affect more than 150 million men worldwide and the number of men with ED is expected to double by the year 2030. Although most cases are not reported, it is estimated that more than 30 million men affected in the United States (U.S).

While ED is more common in men older than age 65, most men older than age 40 experience occasional difficulty; it is estimated that more than 50% of men older than age 40 report periodic episodes of ED. Despite the high number of cases, impotence is greatly undertreated, with only an estimated 15% of men seeking help from a physician due to the fact that they view the condition as personal or embarrassing.

Since the launch of Pfizer's oral drug Viagra (sildenafil) in 1998, there has been a considerable increase in public awareness of ED due to extensive marketing by leading drug manufacturers. As a result, the worldwide market for oral ED drugs has reached more than $4.2 billion.

The U.S. market for ED therapies (defined in this report as including prescription ED drugs and penile implants) is expected to continue stable, moderate growth over the next 5 years. Valued at more than $1.9 billion in 2010, the market is expected to increase at a healthy compound annual rate of 5.1%, with sales reaching more than $2.5 billion in 2015. The U.S. ED therapies market is expected to benefit not only from continued strong demand but from highly positive demographic trends, including a large, growing ED population, strong advertising/marketing, emerging next-generation ED therapies, launch of several lower cost generic drugs, and the continued adoption of improved penile implant systems.

This dynamic report from Medtech Insight includes analyses of products, markets, competitors, and emerging drugs, technology and opportunities. Covered topics in this report include erectile dysfunction drugs (existing and emerging oral and topical ED therapies), injectable and intraurethral agents, vacuum constriction devices, penile implants, and alternative treatments.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

i. Causes and Prevention 
ii. Diagnosis and Treatment 
	a. Oral Drug Therapy 
	b. Injectable and Intraurethral Drug Therapy 
	c. Vacuum Pump Therapy 
	d. Surgery/Penile Prosthesis Implantation 
iii. Erectile Dysfunction Therapies Market 
	a. Drug Therapy 
	b. Penile Implants 
iv. Methodology 

Exhibit ES-1: Erectile Dysfunction Therapies, Combined Market Forecast, 2010-2015 

1. CLINICAL OVERVIEW OF ERECTILE DYSFUNCTION

1.1 Causes and Prevention 
1.2 Diagnosis and Treatment 
	1.2.1 Oral Drug Therapy 
	1.2.2 Injectable and Intraurethral Drug Therapy 
	1.2.3 Vacuum Pump Therapy 
	1.2.4 Surgery/Penile Prosthesis Implantation 
1.3 Emerging Treatments 

2. ERECTILE DYSFUNCTION THERAPIES MARKET

2.1 Drug Therapy 
	2.1.1 Oral Agents 
		2.1.1.1 Eli Lilly 
		2.1.1.2 Bayer HealthCare/Bayer 
		2.1.1.3 Pfizer 
	2.1.2 Injectable and Intraurethral Agents 
		2.1.2.1 Pfizer 
		2.1.2.2 Meda Pharmaceticals/Meda 
	2.1.3 Emerging Drugs 
		2.1.3.1 Oral Agents 
			2.1.3.1.1 Dong-A PharmTech/Dong-A Pharmaceutical 
			2.1.3.1.2 Palatin Technologies 
			2.1.3.1.3 Sanofi-aventis 
			2.1.3.1.4 SK Chemicals/SK Group 
			2.1.3.1.5 Vivus 
			2.1.3.1.6 Discontinued Clinical Development Programs 
				2.1.3.1.6.1 NitroMed 
				2.1.3.1.6.2 Novartis 
				2.1.3.1.6.3 Pfizer 
		2.1.3.2 Topical Agents 
			2.1.3.2.1 Futura Medical 
			2.1.3.2.2 Apricus Biosciences 
	2.1.4 Alternative Treatments 
		2.1.4.1 Pomegranate Extract 
		2.1.4.2 Testosterone Replacement Therapy 
		2.1.4.3 Yohimbine 
		2.1.4.4 Over-the-Counter Herbal Treatments 
2.2 Penile Implants 
	2.2.1 Inflatable Implants 
		2.2.1.1 American Medical Systems/Endo Pharmaceuticals 
		2.2.1.2 Coloplast 
	2.2.2 Noninflatable Implants 
		2.2.2.1 American Medical Systems/Endo Pharmaceuticals 
		2.2.2.2 Coloplast 
2.3 Vacuum Constriction Devices 
	2.3.1 Augusta Medical Systems 
	2.3.2 Timm Medical Technologies/Actient Pharmaceuticals 
	2.3.3 Post-T-Vac Medical 
2.4 Market Analysis 
	2.4.1 Drug Therapy Market 
		2.4.1.1 Patient Volumes 
		2.4.1.2 Market Forecast 
		2.4.1.3 Competitive Analysis 
	2.4.2 Penile Implants Market 
		2.4.2.1 Procedure Volumes 
		2.4.2.2 Market Forecast 
		2.4.2.3 Competitive Analysis 

Exhibit 2-1: Comparative Advantages and Disadvantages of Cialis, Levitra, STAXYN, and Viagra 
Exhibit 2-2: Erectile Function Improvement Using Low-Dose Once-Daily Cialis 
Exhibit 2-3: Erectile Function Improvement Using Low-Dose Once-Daily Cialisin Patients with Diabetes 
Exhibit 2-4: Erectile Function Improvement Using Low-Dose Once-Daily Cialis in Patients with Controlled Hypertension or Cardiovascular Disease 
Exhibit 2-5: Erection Confidence Improvement Using Low-Dose Once-Daily Cialis 
Exhibit 2-6: Common Adverse Events Associated with the Use  of Low-Dose Once-Daily Cialis 
Exhibit 2-7: Erectile Function Improvement Using High-Dose Cialis 
Exhibit 2-8: Erectile Function Improvement Using High-Dose Cialis in Patients with Diabetes 
Exhibit 2-9: Erectile Function Improvement Using High-Dose Cialis in Patients with Controlled Hypertension or Cardiovascular Disease 
Exhibit 2-10: Erection Confidence Improvement Using High-Dose Cialis 
Exhibit 2-11: Common Adverse Events Associated with the Use of High-Dose Cialis 
Exhibit 2-12: STAXYN Orally Disintegrating Tablets 
Exhibit 2-13: Common Adverse Events Associated with the Use of STAXYN 
Exhibit 2-14: Erectile Function Improvement Using Viagra, Pivotal Efficacy Results 
Exhibit 2-15: Steps Involved in the Use of the MUSE Transurethral System 
Exhibit 2-16: 2011, Selected Emerging Erectile Dysfunction Products 
Exhibit 2-17: Benefits and Risks of Penile Implants 
Exhibit 2-18: Advantages and Disadvantages of the AMS 700  Inflatable Penile Implant 
Exhibit 2-19: The AMS 700 LGX Inflatable Penile Implant 
Exhibit 2-20: Advantages and Disadvantages of the AMS Ambicor  Inflatable Penile Implant 
Exhibit 2-21: The Titan and Titan OTR Inflatable Penile Prostheses 
Exhibit 2-22: The Genesis Flexible Rod Implant 
Exhibit 2-23: The SOMAerectStf Vacuum Constriction Device 
Exhibit 2-24: The Vitality OTC Vacuum Constriction Device 
Exhibit 2-25: The Osbon ErecAid Vacuum Therapy System 
Exhibit 2-26: The BOSS 2000-3 and MVP 700 Vacuum Constriction Devices 
Exhibit 2-27: Erectile Dysfunction Drug Therapy, Patient Volumes Forecast, 2010-2015 
Exhibit 2-28: Erectile Dysfunction Drug Therapy, Market Forecast, 2010-2015 
Exhibit 2-29: 2010, Erectile Dysfunction Drug Therapy Market,  Share by Supplier 
Exhibit 2-30: Penile Prosthesis Implantation, Procedure Volumes Forecast, 2010-2015 
Exhibit 2-31: Penile Implants, Market Forecast, 2010-2015 
Exhibit 2-32: 2010, Penile Implants Market, Share by Supplier 

3. COMPANY PROFILES

3.1 American Medical Systems, Inc./Endo Pharmaceuticals Holdings, Inc. 
3.2 Apricus Biosciences, Inc. 
3.3 Bayer AG 
3.4 Futura Medical PLC 
3.5 Eli Lilly and Company 
3.6 Pfizer, Inc. 
3.7 Reckitt Benckiser PLC 
3.8 Vivus, Inc. 


APPENDIX:  COMPANY LISTING


COMPANIES COVERED:

  1. American Medical Systems, Inc./ Endo Pharmaceuticals Holdings, Inc.
  2. Ansell Limited
  3. Apricus Biosciences, Inc.
  4. AstraZeneca PLC
  5. Augusta Medical Systems LLC
  6. Bayer AG
  7. Coloplast AG
  8. Dong-A PharmTech Co. LTD/ Dong-A Pharmaceutical Co. LTD
  9. Firma Medical
  10. Futura Medical PLC
  11. GlaxoSmithKline PLC
  12. Eli Lilly and Company
  13. MEDA Pharmaceuticals, Inc./ MEDA AB
  14. Merck
  15. Mitsubishi Tanabe Pharma Corporation/Mitsubishi Group
  16. NitroMed, Inc.
  17. Novartis International AG
  18. Palatin Technologies, Inc.
  19. Pfizer, Inc.
  20. Plethora Solutions Holdings PLC
  21. Post-T-Vac Medical, Inc.
  22. Reckitt Benckiser Group PLC
  23. Sanofi-aventis
  24. SK Chemicals/ SK Holdings Company LTD
  25. Timm Medical Technologies, Inc.
  26. UCB Group
  27. Vivus, Inc.
  28. Warner Chilcott PLC
Contact Us

Need help finding medtech research? Let us help you!